Vadadustat
Brand names: Vafseo · Active ingredient: Vadadustat
In short: VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Limitations of Use VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being.
What is Vadadustat used for?
VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.
Limitations of Use
VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being.
VAFSEO is not indicated for use:
As a substitute for red blood cell transfusions in patients who require immediate correction of anemia
In patients with anemia due to CKD not on dialysis .
⚠ Boxed warning (FDA's strongest warning)
VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE) .
Targeting a hemoglobin level greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events, as occurs with erythropoietin stimulating agents (ESAs), which also increase erythropoietin levels .
No trial has identified a hemoglobin target level, dose of VAFSEO, or dosing strategy that does not increase these risks .
Use the lowest dose of VAFSEO sufficient to reduce the need for red blood cell transfusions .
Vadadustat dosage
Evaluation of Anemia and Iron Stores
Correct and exclude other causes of anemia (e.g., vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding) before initiation of VAFSEO. Evaluate iron status in all patients before and during treatment. Administer supplemental iron therapy when serum ferritin is less than 100 mcg/L or when serum transferrin saturation is less than 20%. The majority of patients with CKD will require supplemental iron during the course of therapy.
Measure hemoglobin (Hb) at baseline and as recommended in section 2.4.
Liver Testing
Measure serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin prior to the initiation of VAFSEO and monthly after initiation for the first 6 months and then monitor as clinically indicated .
Discontinue VAFSEO if there are persistent ALT or AST elevations greater than 3 times upper limit of normal (ULN) or if ALT or AST elevations greater than 3 times ULN are accompanied by a bilirubin increase greater than 2 times ULN .
Individualize dosing and use the lowest dose of VAFSEO sufficient to reduce the need for red blood cell transfusions. Do not target a hemoglobin level higher than 11 g/dL.
VAFSEO can be taken with or without food.
VAFSEO should be swallowed whole. Tablets should not be cut, crushed, or chewed.
VAFSEO can be administered without regard to the timing or type of dialysis .
If a dose of VAFSEO is missed, it should be taken as soon as possible, unless it is the same day as the next dose. In this case, the missed dose should be skipped, and the next dose taken at the usual time. Double doses should not be taken to make-up for a missed dose.
Adults Not Being Treated with an ESA
The recommended starting dose is 300 mg orally once daily.
Adults Being Switched from an ESA
When converting from an ESA to VAFSEO, the recommended starting dose is 300 mg orally once daily.
Taking into account the gradual rise in Hb with VAFSEO, red blood cell (RBC) transfusions or ESA treatment may be considered during the transition phase if Hb values fall below 9 g/dL or Hb response is considered not acceptable. Patients receiving RBC transfusions should continue VAFSEO treatment during the transfusion period. VAFSEO should be paused for those patients receiving temporary ESA rescue treatment and may be resumed when Hb levels are greater than or equal to 10 g/dL. Depending on the ESA used for rescue, the pause in VAFSEO treatment should be extended to:
2 days after the last dose of epoetin
7 days after the last dose of darbepoetin alfa
14 days after the last dose of methoxy polyethylene glycol-epoetin beta. …
How to take Vadadustat — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Inform patients:
Of the increased risk of death, myocardial infarction, stroke, and thromboembolism including vascular access thrombosis .
That hemoglobin levels will be monitored when initiating or adjusting therapy, every two weeks until stable, then at least monthly .
Of the risk of hepatotoxicity and that liver tests will be measured prior to the initiation of VAFSEO, monthly after initiation for the first 6 months, then as clinically indicated .
Of the risk of hypertension and advise patients of the importance to comply with antihypertensive therapy and monitoring of blood pressure .
Of the risk of seizures and advise patients to contact their healthcare provider for new-onset neurologic symptoms or change in seizure frequency .
Of the risk of gastrointestinal erosions and advise patients to contact their healthcare provider for signs and symptoms of gastric and esophageal erosions and of gastrointestinal bleeding .
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to VAFSEO during pregnancy. …
Warnings & precautions
Do not take this medicine if: VAFSEO is contraindicated in patients:
with a known hypersensitivity to VAFSEO or any of its components .
with uncontrolled hypertension .
VAFSEO increases the risk of arterial and venous thrombotic events, that may be fatal, including myocardial infarction, stroke, venous thromboembolism and vascular access thrombosis . Patients with cardiovascular or cerebrovascular disease are at increased risk of these events. Avoid use in patients with a history of myocardial infarction, cerebrovascular event, or acute coronary syndrome within the 3 months prior to starting VAFSEO.
A rate of hemoglobin rise of greater than 1 g/dL over 2 weeks may contribute to these risks. Targeting a hemoglobin level of greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events, as occurs with ESAs, which also increase erythropoietin levels.
No trial has identified a hemoglobin target level, dose of VAFSEO, or dosing strategy that does not increase these risks. Use the lowest dose of VAFSEO sufficient to reduce the need for red blood cell transfusions. Adherence to dosing and hemoglobin monitoring recommendations is important to avoid excessive erythropoiesis .
Advise patients to seek immediate medical attention if they develop signs or symptoms of myocardial infarction, stroke, venous thromboembolism, or thrombosis of vascular access. Evaluate and manage promptly if these occur.
VAFSEO may cause hepatotoxicity. In clinical trials, hepatocellular injury attributed to VAFSEO was reported in less than 1% of patients, including one case of severe hepatocellular injury with jaundice. All events were asymptomatic and resolved after discontinuation of VAFSEO. The time to onset was generally within the first 3 months of treatment. …
Vadadustat side effects
The following clinically significant adverse reactions are discussed elsewhere in the labeling:
Increased risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access
Hepatotoxicity
Hypertension
Seizures
Gastrointestinal erosion
Serious adverse reactions in patients with anemia due to chronic kidney disease and not on dialysis
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of VAFSEO was evaluated in adults with dialysis-dependent chronic kidney disease (DD-CKD) with anemia in the INNO2VATE-1 and INNO2VATE-2 trials . Both trials randomized patients to VAFSEO or darbepoetin alfa. Results in this section are based on the pooled VAFSEO treatment arms and pooled darbepoetin alfa arms from these trials.
There were 1947 patients treated with VAFSEO and 1955 patients treated with darbepoetin alfa. In the pooled VAFSEO treatment arm, 71% of the participants were treated continuously for at least 6 months of VAFSEO and 44% of participants received VAFSEO for at least 1 year.
VAFSEO was non-inferior to darbepoetin alfa on the time to first occurrence of major adverse cardiovascular events (MACE) in adults with anemia due to CKD who were on dialysis . …
Drug interactions
Table 3 describes clinically significant drug interactions where concomitant use of another drug affects VAFSEO.
Table 3 Drug Interactions with VAFSEO that Affect Vadadustat Exposure
Iron supplements and phosphate binders
Clinical Effect | Co-administration with oral iron supplements, products containing iron, or phosphate binders decreases the exposure of vadadustat , which may reduce the effectiveness of VAFSEO.
Prevention or Management | Stagger administration when VAFSEO is used with oral iron supplements, products containing iron, iron-containing phosphate binders, or non-iron-containing phosphate binders .
Examples* | Iron supplements: ferric citrate, ferrous sulfate, sodium ferrous citrate
Iron-containing phosphate binders: ferric citrate, sucroferric oxyhydroxide
Non-iron-containing phosphate binders: calcium acetate, sevelamer carbonate
Organic anion transporter (OAT) OAT1/OAT3 inhibitors
Clinical Effect | Co-administration with OAT1/OAT3 (Organic Anion Transporter) inhibitors may increase the area under the concentration curve (AUC) of vadadustat , which may increase the risk of VAFSEO adverse reactions.
Prevention or Management | Closely monitor for too large or too rapid an increase in Hb response and for adverse reactions. …
About this medicine
VAFSEO contains vadadustat, a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor. Vadadustat is 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid. Vadadustat has a molecular weight of 306.70. The empirical formula is C14H11ClN2O4.
The chemical structure is:
Vadadustat is a white to off-white solid that is practically insoluble in water.
Vadadustat is formulated as a film-coated, immediate-release tablet for oral administration.
VAFSEO is available in 150 mg, 300 mg and 450 mg strengths. Inactive ingredients include: colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The tablet film-coating contains polyvinyl alcohol, polyethylene glycol (PEG) and talc.
Colorants include:150 mg tablet - titanium dioxide300 mg tablet - titanium dioxide and yellow iron oxide450 mg tablet - titanium dioxide, iron oxide red and ferrosoferric oxide
How it works: Vadadustat is a reversible inhibitor of HIF-prolyl-4-hydroxylases (PH)1, PH2, and PH3 (IC50 in the nM range). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ac9da724-5a62-4ab6-a89c-376a25f6195b. Read the full official label on DailyMed.